Citations (55)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Niknam Riyahi, Ava Safaroghli-Azar, Negar Sheikh-Zeineddini, Mohamad Sayyadi & Davood Bashash. (2019) Synergistic Effects of PI3K and c-Myc Co-targeting in Acute Leukemia: Shedding New Light on Resistance to Selective PI3K-δ Inhibitor CAL-101. Cancer Investigation 37:7, pages 311-324.
Read now
Read now
Joo Hyun Kim, Won Seog Kim, Kyungju Ryu, Seok Jin Kim & Chaehwa Park. (2016) CD79B limits response of diffuse large B cell lymphoma to ibrutinib. Leukemia & Lymphoma 57:6, pages 1413-1422.
Read now
Read now
Rachel E. Hayden, Racha Kussaibati, Laura M. Cronin, Guy Pratt, Claudia Roberts, Mark T. Drayson & Christopher M. Bunce. (2015) Bezafibrate and medroxyprogesterone acetate target resting and CD40L-stimulated primary marginal zone lymphoma and show promise in indolent B-cell non-Hodgkin lymphomas. Leukemia & Lymphoma 56:4, pages 1079-1087.
Read now
Read now
Jorge J Castillo, Meera Iyengar, Benjamin Kuritzky & Kenneth D Bishop. (2014) Isotype-specific inhibition of the phosphatidylinositol-3-kinase pathway in hematologic malignancies. OncoTargets and Therapy 7, pages 333-342.
Read now
Read now
Peter S. Nakhla, James N. Butera, Diana O. Treaba, Jorge J. Castillo & Peter J. Quesenberry. (2013) Spontaneous regression of chronic lymphocytic leukemia to a monoclonal B-lymphocytosis or to a normal phenotype. Leukemia & Lymphoma 54:8, pages 1647-1651.
Read now
Read now
Kamal D. Puri, Julie A. Di Paolo & Michael R. Gold. (2013) B-Cell Receptor Signaling Inhibitors for Treatment of Autoimmune Inflammatory Diseases and B-Cell Malignancies. International Reviews of Immunology 32:4, pages 397-427.
Read now
Read now
Tadeusz Robak & Pawel Robak. (2013) BCR Signaling in Chronic Lymphocytic Leukemia and Related Inhibitors Currently in Clinical Studies. International Reviews of Immunology 32:4, pages 358-376.
Read now
Read now
Martin Dreyling, Hanneke C. Kluin-Nelemans, Sílvia Beà, Wolfram Klapper, Niclas Vogt, Marie-Helene Delfau-Larue, Grit Hutter, Chan Cheah, Annalisa Chiappella, Sergio Cortelazzo, Christiane Pott, Georg Hess, Carlo Visco, Umberto Vitolo, Pavel Klener, Igor Aurer, Michael Unterhalt, Vincent Ribrag, Eva Hoster & Olivier Hermine. (2013) Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network. Leukemia & Lymphoma 54:4, pages 699-707.
Read now
Read now
Chanse Fyffe & Marco Falasca. (2013) 3-Phosphoinositide-dependent protein kinase-1 as an emerging target in the management of breast cancer. Cancer Management and Research 5, pages 271-280.
Read now
Read now
Peter Norman. (2012) Evaluation of WO2012037204 and WO2012037226: Exelixis' selective PI3Kδ inhibitors; the basis of a US$251 million deal. Expert Opinion on Therapeutic Patents 22:8, pages 971-976.
Read now
Read now
Ryan D Gentzler, Jessica K Altman & Leonidas C Platanias. (2012) An overview of the mTOR pathway as a target in cancer therapy. Expert Opinion on Therapeutic Targets 16:5, pages 481-489.
Read now
Read now
Articles from other publishers (44)
Jingyu Zhu, Kan Li, Lei Xu, Yanfei Cai, Yun Chen, Xinling Zhao, Huazhong Li, Gang Huang & Jian Jin. (2022) Discovery of novel selective PI3Kγ inhibitors through combining machine learning-based virtual screening with multiple protein structures and bio-evaluation. Journal of Advanced Research 36, pages 1-13.
Crossref
Crossref
Cristina Cuesta, Cristina Arévalo-Alameda & Esther Castellano. (2021) The Importance of Being PI3K in the RAS Signaling Network. Genes 12:7, pages 1094.
Crossref
Crossref
Jingyu Zhu, Kan Li, Li Yu, Yun Chen, Yanfei Cai, Jian Jin & Tingjun Hou. (2020) Targeting phosphatidylinositol 3‐kinase gamma (PI3Kγ): Discovery and development of its selective inhibitors. Medicinal Research Reviews 41:3, pages 1599-1621.
Crossref
Crossref
Seulki Lee, Eun Ji Choi, Eun Ju Cho, Yun Bin Lee, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon & Yoon Jun Kim. (2020) Inhibition of PI3K/Akt signaling suppresses epithelial-to-mesenchymal transition in hepatocellular carcinoma through the Snail/GSK-3/beta-catenin pathway. Clinical and Molecular Hepatology 26:4, pages 529-539.
Crossref
Crossref
Lydia Xenou & Evangelia A. Papakonstanti. (2020) p110δ PI3K as a therapeutic target of solid tumours. Clinical Science 134:12, pages 1377-1397.
Crossref
Crossref
Rand Arafeh & Yardena Samuels. (2019) PIK3CA in cancer: The past 30 years. Seminars in Cancer Biology 59, pages 36-49.
Crossref
Crossref
Claudio ScuoppoJiguang WangMirjana PersaudSandeep K. MittanKatia BassoLaura PasqualucciRaul RabadanGiorgio InghiramiCarla GrandoriFrancesc BoschRiccardo Dalla-Favera. (2019) Repurposing dasatinib for diffuse large B cell lymphoma. Proceedings of the National Academy of Sciences 116:34, pages 16981-16986.
Crossref
Crossref
Xiliang Du, Xiaobing Li, Liang Chen, Min Zhang, Lin Lei, Wenwen Gao, Zhen Shi, Yuhao Dong, Zhe Wang, Xinwei Li & Guowen Liu. (2018) Hepatic miR‐125b inhibits insulin signaling pathway by targeting PIK3CD. Journal of Cellular Physiology 233:8, pages 6052-6066.
Crossref
Crossref
Evangelia Goulielmaki, Miriam Bermudez-Brito, Margarita Andreou, Niki Tzenaki, Maria Tzardi, Eelco de Bree, Eleftheria Tsentelierou, Antonis Makrigiannakis & Evangelia A. Papakonstanti. (2018) Pharmacological inactivation of the PI3K p110δ prevents breast tumour progression by targeting cancer cells and macrophages. Cell Death & Disease 9:6.
Crossref
Crossref
Shariful Islam, Eric Vick, Bryan Huber, Carla Morales, Catherine Spier, Laurence Cooke, Eric Weterings & Daruka Mahadevan. (2017) Co-targeting aurora kinase with PD-L1 and PI3K abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma: a novel therapeutic strategy. Oncotarget 8:59, pages 100326-100338.
Crossref
Crossref
Bi-Dar Wang, Kristin Ceniccola, SuJin Hwang, Ramez Andrawis, Anelia Horvath, Jennifer A. Freedman, Jacqueline Olender, Stefan Knapp, Travers Ching, Lana Garmire, Vyomesh Patel, Mariano A. Garcia-Blanco, Steven R. Patierno & Norman H. Lee. (2017) Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer. Nature Communications 8:1.
Crossref
Crossref
M H A van Attekum, S Terpstra, E Slinger, M von Lindern, P D Moerland, A Jongejan, A P Kater & E Eldering. (2017) Macrophages confer survival signals via CCR1-dependent translational MCL-1 induction in chronic lymphocytic leukemia. Oncogene 36:26, pages 3651-3660.
Crossref
Crossref
Jia Liu, Hui-Qing Li, Fu-Xia Zhou, Jie-Wen Yu, Ling Sun & Zhong-Hou Han. (2017) Targeting the mTOR pathway in breast cancer. Tumor Biology 39:6, pages 101042831771082.
Crossref
Crossref
Michelle S. Miller, Sweta Maheshwari, Fiona M. McRobb, Kenneth W. Kinzler, L. Mario Amzel, Bert Vogelstein & Sandra B. Gabelli. (2017) Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design. Bioorganic & Medicinal Chemistry 25:4, pages 1481-1486.
Crossref
Crossref
Klemens Hoegenauer, Nicolas Soldermann, Christina Hebach, Gregory J. Hollingworth, Ian Lewis, Anette von Matt, Alexander B. Smith, Romain M. Wolf, Rainer Wilcken, Dorothea Haasen, Christoph Burkhart & Frédéric Zécri. (2016) Discovery of novel pyrrolidineoxy-substituted heteroaromatics as potent and selective PI3K delta inhibitors with improved physicochemical properties. Bioorganic & Medicinal Chemistry Letters 26:23, pages 5657-5662.
Crossref
Crossref
Chen Zhang, Bingfei Xu & Pian Liu. (2016) Addition of the p110α inhibitor BYL719 overcomes targeted therapy resistance in cells from Her2-positive-PTEN-loss breast cancer. Tumor Biology 37:11, pages 14831-14839.
Crossref
Crossref
Wenli Cui, Shutao Zheng, Xinxia Li, Yuqing Ma, Wei Sang, Ming Liu, Wei Zhang & Xiaoyan Zhou. (2016) PIK3CD promoted proliferation in diffuse large B cell lymphoma through upregulation of c-myc. Tumor Biology 37:9, pages 12767-12777.
Crossref
Crossref
Ingrid A. MayerCarlos L. Arteaga. (2016) The PI3K/AKT Pathway as a Target for Cancer Treatment. Annual Review of Medicine 67:1, pages 11-28.
Crossref
Crossref
Jorge J. Castillo, Steven P. Treon & Matthew S. Davids. (2016) Inhibition of the Bruton Tyrosine Kinase Pathway in B-Cell Lymphoproliferative Disorders. The Cancer Journal 22:1, pages 34-39.
Crossref
Crossref
Charles B Goodwin & Rebecca J. Chan. 2016. PI3K-mTOR in Cancer and Cancer Therapy. PI3K-mTOR in Cancer and Cancer Therapy
181
229
.
Andreas Viardot & Christian Buske. 2015. Management of Hematological Cancer in Older People. Management of Hematological Cancer in Older People
129
141
.
Ouardia I Yahiaoui, Jacques A Nunès, Céline Castanier, Raynier Devillier, Florence Broussais, Aurélie J Fabre, Dalila Naimi, Réda Bouabdallah, Daniel Olive & Luc Xerri. (2014) Constitutive AKT activation in follicular lymphoma. BMC Cancer 14:1.
Crossref
Crossref
Agata Majchrzak, Magdalena Witkowska & Piotr Smolewski. (2014) Inhibition of the PI3K/Akt/mTOR Signaling Pathway in Diffuse Large B-Cell Lymphoma: Current Knowledge and Clinical Significance. Molecules 19:9, pages 14304-14315.
Crossref
Crossref
E Hirsch, E Ciraolo, I Franco, A Ghigo & M Martini. (2013) PI3K in cancer–stroma interactions: bad in seed and ugly in soil. Oncogene 33:24, pages 3083-3090.
Crossref
Crossref
Yujeong Jeong, Daeil Kwon & Sungwoo Hong. (2014) Selective and potent small-molecule inhibitors of PI3Ks. Future Medicinal Chemistry 6:7, pages 737-756.
Crossref
Crossref
Fabienne Schmit, Tamara Utermark, Sen Zhang, Qi Wang, Thanh Von, Thomas M. Roberts & Jean J. Zhao. (2014) PI3K isoform dependence of PTEN-deficient tumors can be altered by the genetic context. Proceedings of the National Academy of Sciences 111:17, pages 6395-6400.
Crossref
Crossref
Wenli Cui, Ying Cai & Xiaoyan Zhou. (2014) Advances in subunits of PI3K class I in cancer. Pathology 46:3, pages 169-176.
Crossref
Crossref
Craig S. Sauter, Juliet N. Barker, Lauren Lechner, Junting Zheng, Sean M. Devlin, Esperanza B. Papadopoulos, Miguel-Angel Perales, Ann A. Jakubowski, Jenna D. Goldberg, Guenther Koehne, Izaskun Ceberio, Sergio Giralt, Andrew D. Zelenetz, Craig H. Moskowitz & Hugo Castro-Malaspina. (2014) A Phase II Study of a Nonmyeloablative Allogeneic Stem Cell Transplant with Peritransplant Rituximab in Patients with B Cell Lymphoid Malignancies: Favorably Durable Event-Free Survival in Chemosensitive Patients. Biology of Blood and Marrow Transplantation 20:3, pages 354-360.
Crossref
Crossref
Gabriele Brachtl, Josefina Piñón Hofbauer, Richard Greil & Tanja Nicole Hartmann. (2013) The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemia. Annals of Hematology 93:3, pages 361-374.
Crossref
Crossref
Bernd Groner & Astrid Weiss. (2013) Targeting Survivin in Cancer: Novel Drug Development Approaches. BioDrugs 28:1, pages 27-39.
Crossref
Crossref
Marguerite Vignon, Marie-Dominique Venon, Olivier Hermine & Richard Delarue. (2013) Management of Mantle Cell Lymphoma in the Elderly: Current and Potential Strategies. Drugs & Aging 30:12, pages 979-986.
Crossref
Crossref
Giuseppe Giaccone & Jean-Charles SoriaSimona Wagner & Janet Dancey. 2013. Targeted Therapies in Oncology, Second Edition. Targeted Therapies in Oncology, Second Edition
81
114
.
Michael Hallek. (2013) Chronic lymphocytic leukemia: 2013 update on diagnosis, risk stratification and treatment. American Journal of Hematology 88:9, pages 803-816.
Crossref
Crossref
Shane Gangatharan & John Kuruvilla. (2013) Relapsed and refractory aggressive NHL: Time for a change. Transfusion and Apheresis Science 49:1, pages 72-79.
Crossref
Crossref
Jonathan H. Schatz, Elisa Oricchio, Soham D. Puvvada & H. Guido Wendel. (2013) Progress against follicular lymphoma. Current Opinion in Hematology 20:4, pages 320-326.
Crossref
Crossref
Girija Dasmahapatra, Hiral Patel, Paul Dent, Richard I. Fisher, Jonathan Friedberg & Steven Grant. (2013)
The Bruton tyrosine kinase (
BTK
) inhibitor
PCI
‐32765 synergistically increases proteasome inhibitor activity in diffuse large‐B cell lymphoma (
DLBCL
) and mantle cell lymphoma (
MCL
) cells sensitive or resistant to bortezomib
. British Journal of Haematology 161:1, pages 43-56.
Crossref
Crossref
Anthony M. Manning. 2013. Drug Discovery. Drug Discovery
43
65
.
Jo-Anne PinsonZhaohua ZhengMichelle S. MillerDavid K. ChalmersIan G. JenningsPhilip E. Thompson. (2012)
l
-Aminoacyl-triazine Derivatives Are Isoform-Selective PI3Kβ Inhibitors That Target Nonconserved Asp862 of PI3Kβ
. ACS Medicinal Chemistry Letters 4:2, pages 206-210.
Crossref
Crossref
Ronit Vogt Sionov. (2013) MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies. ISRN Hematology 2013, pages 1-58.
Crossref
Crossref
Stephanie A. Gregory. (2012) Managing the patient with chronic lymphocytic leukemia: initial evaluation and first-line treatment decisions. Community Oncology 9:12, pages S77-S84.
Crossref
Crossref
Justin Cidado & Ben Ho Park. (2012) Targeting the PI3K/Akt/mTOR Pathway for Breast Cancer Therapy. Journal of Mammary Gland Biology and Neoplasia 17:3-4, pages 205-216.
Crossref
Crossref
Janine Schwamb, Valeska Feldhaus, Michael Baumann, Michaela Patz, Susanne Brodesser, Reinhild Brinker, Julia Claasen, Christian P. Pallasch, Michael Hallek, Clemens-Martin Wendtner & Lukas P. Frenzel. (2012) B-cell receptor triggers drug sensitivity of primary CLL cells by controlling glucosylation of ceramides. Blood 120:19, pages 3978-3985.
Crossref
Crossref
L. Braccini, E. Ciraolo, M. Martini, T. Pirali, G. Germena, K. Rolfo & E. Hirsch. (2012) PI3K keeps the balance between metabolism and cancer. Advances in Biological Regulation 52:3, pages 389-405.
Crossref
Crossref
Peng Wu & Yongzhou Hu. (2012) Small molecules targeting phosphoinositide 3-kinases. MedChemComm 3:11, pages 1337.
Crossref
Crossref